HeartBeam Inc. (NASDAQ: BEAT) has reached a significant turning point following the FDA clearance of its 12-lead ECG synthesis software in December 2025 for arrhythmia assessment, according to a recent article highlighting the company's progress. The clearance resolved an earlier regulatory setback and enabled HeartBeam to transition from a development-stage company to a commercial-stage entity, a move that has prompted analyst Joseph Gunnar & Co. to upgrade the stock from Hold to Buy and raise its 12-month price target to $4 from $1.
The upgrade, detailed in a February 2026 report, reflects progress in cardiac risk detection and the company's advancing commercialization efforts. The report states, "We upgrade HeartBeam to a BUY and High-Risk rating with a raised price target of $4 (from $1), reflecting progress in cardiac risk detection." The article notes that this development represents a pivotal moment for HeartBeam as it moves toward bringing its innovative technology to market.
HeartBeam is developing the first cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions, designed for use in portable devices that can be used wherever the patient is. This platform technology aims to deliver actionable heart intelligence, allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities. The company holds 13 U.S. and 4 international issued patents related to its technology.
The full article is available at IBN.fm/NrrYt. For more information about HeartBeam, visit www.HeartBeam.com. The latest news and updates relating to BEAT can be found in the company's newsroom at IBN.fm/BEAT.
